Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

BOSTON - Schering-Plough's (now Merck's) next-generation hepatitis C therapy narlaprevir may shape up as a better competitor for the Vertex hepatitis C drug telaprevir than Schering's first generation protease inhibitor boceprevir, if the ritonavir-boosted Phase IIa trial for narlaprevir stays true to the initial results

You may also be interested in...

Vertex's Telaprevir Works In Twice Daily Dose; Response-Guided Therapy Cuts Down Drop-Outs

Is it a trick or a treat? AASLD lifts embargo on all annual meeting data at Halloween press conference.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts